These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 7804972)
1. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Rosenberg L; Barkun AN; Denis MH; Pollak M Cancer; 1995 Jan; 75(1):23-8. PubMed ID: 7804972 [TBL] [Abstract][Full Text] [Related]
2. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen]. Wenger FA; Zieren HU; Jacobi CA; Müller JM Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878 [TBL] [Abstract][Full Text] [Related]
3. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen]. Wenger FA; Jacobi CA; Siderow A; Zieren J; Zieren HU; Müller JM Chirurg; 1999 Jun; 70(6):694-9. PubMed ID: 10427457 [TBL] [Abstract][Full Text] [Related]
4. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Wong A; Chan A Cancer; 1993 Apr; 71(7):2200-3. PubMed ID: 8384066 [TBL] [Abstract][Full Text] [Related]
5. [Metastatic breast carcinoma with neuroendocrine differentiation--its combined therapy with tamoxifen and the somatostatin analog octreotide]. Rischke HC; Staib-Sebler E; Mose S; Adams SW; Herrmann G; Böttcher HD; Lorenz M Dtsch Med Wochenschr; 1999 Feb; 124(7):182-6. PubMed ID: 10093577 [TBL] [Abstract][Full Text] [Related]
6. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Ingle JN; Suman VJ; Kardinal CG; Krook JE; Mailliard JA; Veeder MH; Loprinzi CL; Dalton RJ; Hartmann LC; Conover CA; Pollak MN Cancer; 1999 Mar; 85(6):1284-92. PubMed ID: 10189133 [TBL] [Abstract][Full Text] [Related]
7. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723 [TBL] [Abstract][Full Text] [Related]
8. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Bajetta E; Procopio G; Ferrari L; Martinetti A; Zilembo N; Catena L; Alú M; Della TS; Alberti D; Buzzoni R Cancer; 2002 Jan; 94(2):299-304. PubMed ID: 11900215 [TBL] [Abstract][Full Text] [Related]
9. Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomized study with long-term follow-up. Bontenbal M; Foekens JA; Lamberts SW; de Jong FH; van Putten WL; Braun HJ; Burghouts JT; van der Linden GH; Klijn JG Br J Cancer; 1998; 77(1):115-22. PubMed ID: 9459155 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma. Sulkowski U; Büchler M; Pederzoli P; Arnold R; Dinse P; Kay A; Haus U; Beger HG Eur J Cancer; 1999 Dec; 35(13):1805-8. PubMed ID: 10673995 [TBL] [Abstract][Full Text] [Related]
11. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971 [TBL] [Abstract][Full Text] [Related]
12. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Bajetta E; Catena L; Fazio N; Pusceddu S; Biondani P; Blanco G; Ricci S; Aieta M; Pucci F; Valente M; Bianco N; Mauri CM; Spada F Cancer; 2014 Aug; 120(16):2457-63. PubMed ID: 24752410 [TBL] [Abstract][Full Text] [Related]
13. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study. Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733 [TBL] [Abstract][Full Text] [Related]
14. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Friess H; Büchler M; Beglinger C; Weber A; Kunz J; Fritsch K; Dennler HJ; Beger HG Pancreas; 1993 Sep; 8(5):540-5. PubMed ID: 8302789 [TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced pancreatic cancer with high-dose octreotide. Friess H; Büchler M; Ebert M; Malfertheiner P; Dennler HJ; Beger HG Int J Pancreatol; 1993 Dec; 14(3):290-1. PubMed ID: 8113631 [No Abstract] [Full Text] [Related]
16. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study. Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498 [TBL] [Abstract][Full Text] [Related]
17. Tamoxifen or cyproterone acetate in combination with buserelin are ineffective in patients with pancreatic adenocarcinoma. Swarovsky B; Wolf M; Havemann K; Arnold R Oncology; 1993; 50(4):226-9. PubMed ID: 8497375 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Verset G; Verslype C; Reynaert H; Borbath I; Langlet P; Vandebroek A; Peeters M; Houbiers G; Francque S; Arvanitakis M; Van Laethem JL Br J Cancer; 2007 Sep; 97(5):582-8. PubMed ID: 17687341 [TBL] [Abstract][Full Text] [Related]
19. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumour Group. Taylor OM; Benson EA; McMahon MJ Br J Surg; 1993 Mar; 80(3):384-6. PubMed ID: 8472160 [TBL] [Abstract][Full Text] [Related]
20. Role of octreotide in the treatment of pancreatic cancer. Ebert M; Friess H; Beger HG; Büchler MW Digestion; 1994; 55 Suppl 1():48-51. PubMed ID: 8132137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]